

Amendments of the Claims:

A detailed listing of all claims in the application is presented below. This listing of claims will replace all prior versions, and listings, of claims in the application. All claims being currently amended are submitted with markings to indicate the changes that have been made relative to immediate prior version of the claims. The changes in any amended claim are being shown by strikethrough (for deleted matter) or underlined (for added matter).

1. (Currently amended) A method of administering gene therapy or delivering recombinant or foreign polynucleotides to mammalian cells or organisms, comprising the steps of:
 - a) creating a genetically engineered baculovirus having a deletion, inactivation or downregulation of an envelope protein gene of a progenitor baculovirus, from which said engineered baculovirus is derived, wherein said genetically engineered virus is supplied, in trans or cis, with a heterologous envelope protein or a protein or other molecule that facilitates entry of said engineered baculovirus into a cell that is not normally a host of said progenitor ~~baculovirus~~ baculovirus;
 - b) further modifying said engineered baculovirus to express a gene therapy agent or recombinant or foreign polynucleotide; and
 - c) delivering said modified baculovirus into said mammalian cell or organism.
2. (Original) The method of claim 1, wherein said genetically engineered baculovirus has a property of more efficient entry into a non-host cell than said progenitor baculovirus, from which said engineered baculovirus is derived.
3. (Original) The method of claim 1, wherein said genetically engineered baculovirus has a property of more specific targeting of said engineered baculovirus to a specific cell type than said progenitor baculovirus, from which said engineered baculovirus is derived.
4. (Original) The method of claim 1, wherein said genetically engineered baculovirus has a property of more effective evasion of mammalian immune system recognition or inactivation than said progenitor baculovirus, from which said engineered baculovirus is derived.
5. (Original) The method of claim 1, wherein said genetically engineered baculovirus is engineered to express an envelope protein from Vesicular Stomatitis Virus.

6. (Original) The method of claim 5, wherein said envelope protein from Vesicular Stomatitis Virus is VSV-G protein.
7. (Cancelled).
8. (Currently amended) The genetically engineered baculovirus of claim 1 step (a), wherein said genetically engineered baculovirus infects and replicates in at least one permissive insect cell host of said progenitor baculovirus.
9. (Original) The genetically engineered baculovirus of claim 8, wherein said progenitor baculovirus envelope protein is gp64 or a homologous envelope glycoprotein.